NOVN — Novartis AG Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Novartis AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	R2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	49,898	43,974	43,375	46,660	51,722
Cost of Revenue
Gross Profit	35,498	32,583	32,164	34,640	38,907
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	39,746	33,982	35,566	37,085	37,409
Operating Profit	10,152	9,992	7,809	9,575	14,313
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9,878	24,530	7,177	9,123	13,640
Provision for Income Taxes
Net Income After Taxes	8,071	22,905	6,049	8,572	11,939
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	8,072	24,021	6,955	14,850	11,941
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	8,072	24,021	6,955	14,850	11,941
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	4.41	10.6	3.59	5.45	6.58
Dividends per Share